NHL-3 protocol six-drug combination chemotherapy for non-hodgkin's lymphoma

Koziner, Benjamín; Sklaroff, Robert B.; Little, Claudia; Straus, David J.; Lee, Burton J.; Clarkson, Bayard D.; Labriola, Dominic; Thaler, Howard T.; Young, Charles W.; Nisce, Lourdes Z.; Oettgen, Herbert F.

doi:10.1002/1097-0142(19840615)53:12<2592::aid-cncr2820531204>3.0.co;2-7

Cited by 16 publications

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Recent results of multimodal therapy of gastric lymphoma

Shiu

Nisce

Pinna

et al. 1986

Cancer

Self Cite

View full text Add to dashboard Cite

The efficacy of multimodality treatment of gastric lymphoma was examined in a retrospective study of 46 patients treated at the Memorial Sloan-Kettering Cancer Center from 1971 to 1982. The principal treatment plan consisted of surgical resection of the gastric lymphoma (n = 36) where feasible, followed by radiation therapy of the whole abdomen (n = 23) with a boosting dose to the stomach-bed to 3700 cGy, and/or chemotherapy using mainly the CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) regimen as an adjuvant (n = 7), or CHOP plus other drugs for advanced disease. The median follow-up time of patients was 61 months (range, 30 months to 14 years). There was no operative mortality. No patient developed known relapse in the abdomen after resection and total abdominal irradiation, and none suffered relapses after adjuvant chemotherapy, for Stages I-E and II-E. At 5 years, the estimated survival rate after treatment was 95%, 78%, and 25%, respectively for Stages I-E (n = 20), II-E (n = 9) and IV (n = 17). The results for Stage I-E and II-E resectable tumors were significantly improved (P less than 0.05 and less than 0.1 respectively) over those of similar tumors treated in 1949 to 1970.

show abstract

Recent results of multimodal therapy of gastric lymphoma

Shiu

Nisce

Pinna

et al. 1986

Cancer

Self Cite

View full text Add to dashboard Cite

show abstract

Peripheral T-cell lymphoma

Armitage

Greer

Levine

et al. 1989

Cancer

112

View full text Add to dashboard Cite

Peripheral T-cell lymphoma is the most common type of T-cell lymphoma seen in adults in the United States. Clinical data were reviewed from 134 cases of peripheral T-cell lymphoma diagnosed in three centers. The median age of the patients was 57 years (range, 4-97 years), 59% were male, and 36 patients (27%) had a history of a preceding disorder of the immune system. The tumors were grouped histologically into large cell (43%), mixed large and small cell (40%), and small cell (17%). The stage at diagnosis was I (7%), II (21%), III (22%), and IV (50%). B symptoms were present in 57%. The most frequent sites of extranodal involvement were bone marrow (35%), skin (13%), and lung (11%). Eighty patients were treated with a multiagent chemotherapy regimen with proven curative potential in aggressive non-Hodgkin's lymphomas and the remainder of the patients received less intensive chemotherapy (36 patients), radiotherapy (nine patients), or no treatment (nine patients). Fifty percent of the intensively treated patients achieved complete remission and the actuarial 4-year survival was 45%. However, the 4-year, disease-free survival in patients with Stage IV disease was only 10%. Although peripheral T-cell lymphomas appeared similar in many ways to their B-cell counterparts, disease-free survival by stage was low and patients with Stage IV disease had an especially poor outlook.

show abstract